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Synopsis	
	 Pulmonary	metastasis	can	be	present	in	as	frequently	as	88%	and	80%,	respectively,	of	
patients	with	sarcoma	and	germ	cell	tumour	with	metastatic	disease.		In	both	sarcoma	and	germ	
cell	tumour,	pulmonary	metastatectomy	may	be	the	only	means	of	rendering	a	patient	disease-
free.		Sublobar	(wedge	or	segmentectomy),	lobectomy,	and,	rarely,	pneumonectomy	can	be	
safely	performed	to	achieve	complete	resection.		Bilateral	disease	can	be	resected	via	staged	
thoracoscopy/thoracotomy,	median	sternotomy,	or	clamshell	thoracotomy.		Finally,	multiple	
resections	and	re-resections	in	select	patients	have	resulted	in	improved	survival.		The	main	
principle	of	pulmonary	metastatectomy	is	complete	resection.		In	the	appropriately	selected	
patient	5-yr	survival	rates	of	as	high	as	35-52%	for	sarcoma,	and	80%	for	germ	cell	tumour	can	
be	realized.	 	
Key	points	
- Patients	with	controlled	primary	site	of	disease,	absent	extra-thoracic	(or	if	
oligometastasis,	other	sites	are	controlled	or	controllable),	sufficient	pulmonary	
function	and	overall	functional	capacity	to	undergo	pulmonary	resection	who	have	
pulmonary	metastases	that	can	be	completely	resected	are	candidates	for	pulmonary	
metastatectomy.	
	
- Patients	undergoing	pulmonary	metastatectomy	of	osteosarcoma	may	have	a	5-yr	
survival	as	high	as	35-50%.		The	5-year	survival	of	patients	undergoing	resection	of	soft	
tissue	sarcoma	metastases	has	been	reported	to	be	as	high	as	35-52%.	
	
- Large	case	series	of	pulmonary	metastatectomy	of	nonseminomatous	germ	cell	tumour	
(NSGCT)	have	reported	5-year	survival	rates	greater	than	80%.	
	
- There	are	no	randomized	trials	on	pulmonary	metastatectomy	in	patients	with	
metastatic	sarcoma	or	NSGCT.		Survival	rates	are	from	case	series	of	selected	patients	
without	observation	control	arms	for	comparison.	
	 	
Introduction:	Nature	of	the	Problem	
	 Pulmonary	metastatectomy	dates	back	to	the	1880s	(1).		Sublobar	resections,	
lobectomy	and	pneumonectomy	were	subsequently	described	in	the	setting	of	metastatic	
sarcoma,	renal	cell	cancer	and	colon	cancer	(2,	3).		Selection	criteria	for	pulmonary	
metastatectomy	were	formally	proposed	in	a	case	series	of	pulmonary	metastatectomies	by	
Alexander	and	Haight	(4).		Since	then,	with	increasing	supportive	data	pulmonary	
metastatectomy	has	become	a	widely	accepted	treatment	modality	for	patients	with	metastatic	
disease.	
	 As	high	as	88%	of	patients	with	sarcoma	were	found	to	have	single-site	pulmonary	
metastatic	disease	in	a	retrospective	study	by	Huth	and	Eilber	(5).		In	a	case	series	from	
Memorial	Sloan-Kettering	Cancer	Center,	Billingsley	reported	that	73%	of	230	patients	with	
recurrent	soft	tissue	sarcoma	had	recurrences	that	initially	appeared	in	the	lungs	(6).		Eight	
percent	of	patients	with	clinical	Stage	I	nonseminomatous	germ	cell	tumour	(NSGCT)	will	
develop	pulmonary	metastases.		Additionally,	an	estimated	10-20%	of	patients	with	Stage	III	
disease	who	were	treated	with	cisplatin-based	chemotherapy	will	have	residual	intrathoracic	
disease	requiring	mediastinal	dissection	or	pulmonary	metastatectomy	(7).		Pulmonary	
metastatectomy	may	be	the	only	therapeutic	option	to	render	these	patients	disease-free.	
	
Therapeutic	Options	and/or	Surgical	Technique	
	 Following	systemic	therapy	and	confirmation	of	limited	disease,	therapeutic	options	for	
controlled	pulmonary	metastases	include	continued	systemic	chemotherapy,	isolated	lung	
perfusion	or	suffusion,	radiofrequency	ablation,	stereotactic	body	radiation	therapy,	and	
surgical	resection.		Isolated	lung	perfusion	or	suffusion,	radiofrequency	ablation,	and	
stereotactic	body	radiation	therapy	will	be	covered	more	thoroughly	elsewhere	in	this	issue.	
	 Patients	being	considered	for	pulmonary	metastatectomy	should	meet	the	following	
criteria:	(1)	controlled	primary	site	of	disease,	(2)	absence	of	extrathoracic	metastases	(or,	in	
cases	of	oligometastases,	extrathoracic	sites	of	metastases	are	controlled	or	controllable),	(3)	
sufficient	pulmonary	reserve	to	tolerate	the	proposed	pulmonary	resection,	(4)	complete	
resection	of	all	pulmonary	metastatic	disease	can	be	achieved	with	proposed	pulmonary	
resection.		Pre-operative	planning	should	include	pulmonary	function	testing	and	an	evaluation	
of	the	patient’s	ability	to	tolerate	an	operation.		Special	consideration	should	be	taken	for	
patients	receiving	certain	chemotherapeutic	agents	(bleomycin,	mitomycin	C,	busulfan,	
cyclophosphamide,	carmustine,	gefitinib,	paclitaxel	and	methotrexate).		These	patients	are	at	
risk	for	drug-induced	lung	disease,	including	interstitial	pneumonitis	and	fibrosis,	
hypersensitivity	pneumonitis	and	acute	pneumonia.		Fractional	inspired	oxygen	(FiO2)	should	be	
minimized	in	order	to	minimize	the	risk	of	oxygen	toxicity.		Finally,	patients	should	be	required	
to	engage	in	smoking	cessation	for	at	least	3	weeks	prior	to	surgery	in	order	to	reduce	the	risk	of	
postoperative	pneumonia	and	other	complications.						
	 Pulmonary	metastatectomy	can	be	achieved	via	thoracoscopy	or	thoracotomy	for	
unilateral	disease.		Patients	with	bilateral	pulmonary	metastases	can	undergo	bilateral	
thoracoscopy/thoracotomy,	median	sternotomy	or	clamshell	thoracotomy.		Proponents	of	open	
resection	argue	that	more	pulmonary	nodules	can	be	identified	with	manual	palpation	(8-11).		
The	identification	of	more	nodules,	however,	does	not	translate	to	improved	survival	(12),	and	
proponents	of	thoracoscopy	argue	that	patients	undergoing	thoracotomy	experience	
significantly	more	complications	(11).		The	European	Society	of	Thoracic	Surgeons	(ESTS)	
working	group	addressed	several	key	issues	to	take	into	consideration	in	this	decision-making	
process	(12).		The	ESTS	considers	open	and	thoracoscopic	approaches	equivalent,	advising	that	
surgeons	should	use	the	technique	that	the	surgeon	is	most	comfortable	with.		Additionally,	
there	are	no	data	demonstrating	a	difference	in	outcome	between	an	initial	policy	of	bilateral	
versus	unilateral	exploration	or	simultaneous	versus	staged	approach	in	patients	with	known	
bilateral	disease.		Results	from	the	ESTS	working	group	survey	suggested	that	an	initial	approach	
via	median	sternotomy	is	acceptable.		In	cases	not	suitable	for	median	sternotomy--such	as	
posterior	lesions	or	patients	with	previous	pulmonary	resection--staged	thoracotomy	with	a	3-6	
week	interval	was	recommended.		Zheng	and	colleagues	recommended	a	similar	approach	to	
pulmonary	metastatectomy	except	that	these	authors	were	more	supportive	of	a	thoracoscopic	
approach	(13).	
Ultimately,	the	main	principle	of	surgical	resection	of	pulmonary	metastases	is	complete	
resection.		When	possible,	preservation	of	pulmonary	function	should	be	maximized	by	limiting	
resection.		Peripheral	nodules	can	be	treated	with	a	wedge	resection.		More	central	nodules	
may	require	a	segmentectomy	or	lobectomy.		Very	rarely,	a	pneumonectomy	may	be	necessary	
to	achieve	complete	resection.	
	
Clinical	Outcomes	
Sarcoma	
	 In	a	study	by	the	Cooperative	Osteosarcoma	Study	group,	81%	of	patients	with	sarcoma	
presenting	with	metastatic	disease	had	pulmonary	metastases	(14).		Sixty-two	percent	of	these	
patients	have	metastatic	disease	in	the	lungs	only.		As	sarcoma	often	does	not	respond	to	
systemic	or	radiation	therapy,	complete	resection	with	a	pulmonary	metastatectomy	may	be	
the	only	means	by	which	to	render	a	patient	with	single-site	sarcoma	metastasis	free	of	disease.	
	 There	are	few	prospective	studies	and	no	randomized	trials	evaluating	the	role	of	
pulmonary	metastatectomy	in	the	management	of	patients	with	osteogenic	sarcoma.		The	first	
significant	case	series	was	described	by	Martini,	whereupon	the	authors	describe	twenty-two	
patients	who	collectively	underwent	59	procedures	for	the	resection	of	152	nodules	(15).		The	
authors	reported	a	3-yr	survival	rate	of	45%.		Similarly,	in	subsequent	case	series,	Snyder	and	
Putnam	in	their	series	of	21	and	39	patients,	respectively,	both	reported	5-year	survival	rates	of	
nearly	40%	in	patients	with	osteogenic	sarcoma	who	underwent	pulmonary	metastatectomy	(16,	
17).		The	presence	of	three	or	fewer	nodules	on	preoperative	imaging	was	found	to	be	the	single	
most	useful	preoperative	risk	factor.	
	 In	more	recent	case	series,	Kim,	et	al	published	their	results	from	Massachusetts	
General	Hospital	consisting	of	97	patients	who	underwent	pulmonary	metastatectomy	between	
June	2002	and	December	2008	(18).		They	reported	an	overall	5-yr	survival	of	50.1%	and	noted	
that	patients	with	a	disease-free	interval	<12mths	(p=0.001),	two	or	more	pulmonary	
metastases	(p=0.0007),	a	lesion	>3cm	in	diameter	(p=0.017),	and	a	positive	resection	margin	
(p=0.004)	had	a	worse	survival.		Conversely,	histology,	tumour	grade	and	use	of	chemotherapy	
were	found	to	have	no	effect	on	survival.		Authors	from	the	University	of	California	Los	Angeles	
reported	results	from	the	sarcoma	database	including	data	from	47	patients	with	osteosarcoma.		
They	found	that	on	multivariable	analysis	age	>45	years,	disease-free	interval	<1yr,	synchronous	
disease,	thoracotomy,	histology	and	performance	of	lobectomy	were	associated	with	poor	
overall	survival	(19).		Moreover,	patients	with	an	increasing	number	of	risk	factors	were	
associated	with	a	poor	overall	survival	(64%	at	5	years	for	patients	with	3	risk	factors	vs.	3%	at	5	
years	for	patients	with	5	risk	factors).		Finally,	a	multi-institutional	review	of	39	pediatric	cases	of	
metastatic	osteosarcoma	presenting	with	pulmonary	metastases	more	than	one	year	after	
primary	site	diagnosis	reported	a	post-resection	event	free	survival	of	33%	at	5	years	and	post-
resection	survival	of	56.8%	at	5yrs	(20).		These	authors	concluded	that	long-term	survivors	in	
patients	who	presented	with	pulmonary	metastases	are	possible	(53%	post-resection	overall	
survival	at	10	years).		They	endorsed	pulmonary	metastatectomy	and	reported	that	the	addition	
chemotherapy	did	not	add	benefit.	
	 Patients	with	soft	tissue	sarcoma	are	distinct	from	those	with	osteosarcoma.		Soft	tissue	
sarcomas	are	non-ossifying	tumors	arising	from	connective	tissue	elements.			Approximately	
23%	of	patients	with	soft	tissue	sarcoma	will	develop	distant	metastases	(6).		As	with	
osteosarcoma,	the	lung	is	the	most	common	metastatic	site,	accounting	for	up	to	80%	of	
metastases	(21).		Pulmonary	metastatectomy,	similarly,	represents	the	only	potentially	curative	
treatment	for	patients	with	soft	tissue	sarcoma	and	pulmonary	dissemination	(22,	23).	
	 The	first	soft	tissue	sarcoma	pulmonary	metastatectomy	was	described	by	Weinlechner,	
at	which	time	2	incidentally	found	lesions	were	removed	during	a	resection	of	a	chest	wall	
sarcoma	(24).		Since	then,	Van	Geel	and	Sardenberg	have	published	their	case	series.		Van	Geel	
and	colleagues	reported	a	5-year	survival	of	38%	for	patients	with	soft	tissue	sarcoma	
undergoing	pulmonary	metastatectomy	in	their	case	series	of	255	patients	(25).		Sardenberg	
reported	a	7.5-year	survival	rate	of	34.7%	(26).		Finally,	the	authors	at	the	University	of	
Pennsylvania	report	3-yr	and	5-yr	overall	survival	rates	of	67%	and	52%,	respectively,	from	their	
series	of	48	patients	undergoing	metastatectomy	for	soft	tissue	sarcoma	(27).		The	authors	do	
concede	that	their	improved	results	compared	to	historical	controls	were	likely	due	to	careful	
patient	selection.		As	with	other	primary	sites,	a	longer	disease-free	interval	(greater	than	6	
months)	and	fewer	than	3	nodules	are	associated	with	a	higher	overall	5-year	survival.		
Repeated	pulmonary	metastatectomy	was	also	associated	with	improved	survival	(28,	29).		
However,	patients	with	soft	tissue	sarcoma	presenting	with	synchronous	pulmonary	metastasis	
were	not	found	to	benefit	from	metastatectomy,	and	thus	should	be	considered	for	clinical	trials	
(30,	31).	
Treasure,	et	al	performed	a	systematic	review	of	published	case	series	on	pulmonary	
metastatectomy	for	sarcoma	(32).		Eighteen	studies	published	between	1991	and	2010	were	
included,	involving	1357	patients,	43%	of	whom	underwent	subsequent	metastatectomy.			The	
reported	5-year	survival	for	patients	with	osteosarcoma	was	34%.		The	reported	5-year	survival	
for	patients	with	soft	tissue	sarcoma	was	25%.		In	comparison,	the	5-year	survival	reported	from	
data	from	the	Thames	Cancer	Registry	was	20-25%	and	13-15%	in	patients	with	bone	sarcoma	
and	soft	tissue	sarcoma,	respectively.		Improved	survival	was	associated	with	the	presence	of	
fewer	metastatic	lesion	and	longer	disease-free	intervals.		The	authors,	however,	were	very	
implicit	in	stating	that	there	was	no	evidence	to	support	that	survival	improvement	was	
attributable	to	metastatectomy	as	there	were	no	controls	nor	was	treatment	randomized	in	any	
of	the	studies	included	in	the	review.		The	authors	proposed	that	improved	patient	survival	was	
a	result	of	the	process	of	patient	selection	and	not	an	effect	of	metastatectomy.		Aberg	
published	similar	views	were	previously	(33,	34).		The	authors	emphasize	the	need	for	
randomized	trials	to	determine	the	true,	and	not	the	perceived,	effect	of	pulmonary	
metastatectomy.	
Germ	Cell	Tumours	
	 When	discussing	pulmonary	metastatectomy	for	germ	cell	tumour	(GCT),	it	is	typically	in	
reference	to	nonseminomatous	germ	cell	tumour	(NSGCT).		Metastatectomy	in	seminoma	has	a	
limited	role,	but	has	been	advocated	in	the	setting	of	residual	masses	>	3cm	(35).		This	is	on	
account	of	the	fact	that	viable	disease	or	relapse	in	patients	with	seminoma	has	been	noted	in	
cases	with	residual	masses	>	3cm	at	a	rate	of	27%,	compared	to	a	rate	of	3%	in	cases	with	
residual	masses	<	3cm	or	no	residual	masses	on	computed	tomography	(36).		There	are	no	
reliable	survival	data	on	pulmonary	metastatectomy	for	seminoma,	however.		The	practice	at	
Indiana	University	is	to	follow	patients	with	residual	disease	with	serial	computed	tomography,	
considering	surgical	intervention	only	in	patients	with	growth	of	the	residual	mass	in	patients	
with	teratoma	on	testicular	pathology.		Conversely,	pulmonary	metastatectomy	in	NSGCT	is	
widely	accepted	with	good	long-term	results.		In	fact,	data	from	the	international	registry	of	lung	
metastasis	identified	patients	with	germ	cell	tumours	(p=0.04)	as	being	associated	with	a	better	
prognosis	than	patients	with	pulmonary	metastases	from	other	malignancies.	
	 Due	to	excellent	results	from	effective	chemotherapy	therapy	regimens,	pulmonary	
metastatectomy	for	NSGCT	currently	serves	an	adjunct	role	in	the	treatment	of	patients	with	
metastatic	NSGCT.		All	patients	with	persistent	pulmonary	nodules	on	radiologic	imaging	
following	systemic	therapy	should	be	considered	for	resection.		However,	only	5-10%	of	patients	
with	metastatic	NSGCT	will	require	pulmonary	metastatectomy	(37).		Steyerber,	et	al	reported	
that	histology	at	residual	retroperitoneal	lymph	node	dissection	(RPLND)	was	a	strong	predictor	
of	histology	at	thoracotomy	(38).		However,	several	authors	have	reported	pathology	from	
residual	RPLND	to	differ	from	pathology	from	residual	pulmonary	nodules	in	as	high	as	30%	of	
cases	(39-42).		Therefore,	pulmonary	metastatectomy	should	be	at	least	considered	even	in	
cases	with	necrosis	or	fibrosis	on	RPLND.	
	 Five-year	survival	rates	of	as	high	as	79-87%	were	reported	in	early,	small	case	series	of	
less	than	forty	patients	(39,	41,	42).		Memorial	Sloan-Kettering	Cancer	Center	published	the	first	
single-institution	large	case	series	of	157	patients	undergoing	pulmonary	metastatectomy	for	
germ	cell	tumour	(between	July	1967	and	May	1995).		Forty-four	percent	of	patients	had	viable	
tumour	in	the	resected	specimen,	and	26%	of	patients	had	metastases	to	other	sites.		Overall	5-
yr	survival	after	pulmonary	resection	was	68%,	but	82%	for	patients	diagnosed	after	1985,	when	
cisplatin-based	chemotherapy	regimens	for	NSGCT	were	introduced	(43).		Persistent	carcinoma	
in	the	specimen	(p<0.0001),	and	concurrent	metastases	to	non-pulmonary,	visceral	sites	
(p=0.0069)	were	negative	prognostic	factors.			
In	2005,	Kesler,	et	al	reported	Indiana	University’s	series	of	patients	with	metastatic	
NSGCT,	fifty-nine	and	26	of	whom	had	pulmonary	metastases	and	both	mediastinal	and	
pulmonary	metastases,	respectively,	as	salvage	therapy	(44).		Median	survival	was	5.6	years,	and	
it	was	reported	that	after	a	mean	follow-up	of	5.1years	42.3%	of	patients	were	alive	and	without	
disease.		Older	age,	pulmonary	metastases	(versus	mediastinal	metastases),	and	>	4	total	
intrathoracic	lesions	were	found	to	be	significantly	predictive	of	worse	long-term	survival.		In	
2011,	Kesler,	et	al	reported	the	complete	series	of	159	patients	undergoing	pulmonary	
metastatectomy	and	136	patients	undergoing	both	pulmonary	and	mediastinal	metastatectomy	
(45).		More	than	half	(52.7%)	of	patients	were	noted	to	have	teratoma,	21.5%	had	necrosis,	15%	
persistent	NSGCT	and	10.1%	degenerative	non-germ	cell	cancer.		Median	survival	was	23.5	years	
and	more	than	68%	of	patients	were	alive	without	disease	after	a	mean	of	5.6years.		Older	age	
at	dx	(p=0.001),	non-germ-cell	cancer	in	testes	specimen	(p=0.004),	residual	disease	(p<0.001)	
were	significantly	predictive	of	survival.		Survival	was	the	same	in	patients	with	hematogenous	
versus	lymphatic	metastases.		Finally,	the	authors	reported	that	residual	pathology	was	the	
driving	predictor	of	survival.	
	 Simultaneous	pulmonary	metastatectomy	and	RPLND	could	be	performed	
simultaneously	with	acceptable	morbidity	and	mortality	(46).		Similarly,	pulmonary	
metastatectomy	via	staged	thoracotomy	or	clamshell	thoracotomy	have	been	described	for	
bilateral	pulmonary	disease	with	low	morbidity.		However,	Besse,	et	al	suggests	that	in	certain	
circumstances	bilateral	exploration	could	be	avoided	(47).		The	authors	reported	their	results	
from	a	multi-institutional	retrospective	review	of	71	patients	with	residual	pulmonary	lesion	
following	cisplatin-based	chemotherapy.		Of	39	patients	with	bilateral	pulmonary	disease,	2	(5%)	
had	discordant	histologic	results.		Moreover,	of	20	patients	with	necrosis	on	initial	pulmonary	
metastatectomy,	1	(5%)	had	teratoma	on	the	contralateral	lung.		The	authors	concluded	that	
with	95%	pathologic	concordance	rate	between	the	two	lungs,	contralateral	pulmonary	
metastatectomy	could	be	avoided	when	complete	necrosis	is	found	on	the	initial	side	
pulmonary	resection.	
	
Complications	and	Concerns	
	 Complete	pulmonary	metastatectomy	can	be	achieved	with	low	morbidity	and	mortality.		
Surgical	mortality	is	akin	to	pulmonary	resection	for	other	diagnoses	(0-0.6%)	(39,	41-43).		A	
surgical	mortality	of	<1%	was	reported	in	pulmonary	metastatectomy	in	the	Indiana	University	
series	(45).		However,	the	majority	of	surgical	mortalities	were	in	patients	undergoing	
simultaneous	resection	of	pulmonary	and	mediastinal	disease.		The	most	commonly	reported	
complications	are	pneumonia,	respiratory	failure,	atrial	fibrillation,	prolonged	air	leak	and	
prolonged	ventilation	(19).		Chyle	leaks	can	also	occur	in	patients	with	NSGCT	who	are	
concurrently	undergoing	an	extensive	lymphadenectomy	for	residual	mediastinal	NSGCT	lesions	
(45).	
	Summary	
Pulmonary	metastatectomy	plays	a	central	role	in	the	treatment	of	patients	with	
metastatic	sarcoma	and	germ	cell	tumour.		Five-year	survival	rates	can	be	as	high	as	50%	for	
patients	with	sarcoma	and	80%	for	patients	with	NSGCT.		These	survival	rates	are	significantly	
improved	compared	to	historical	controls.		Current	data	in	support	of	pulmonary	
metastatectomy	for	sarcoma	and	NSGCT,	however,	are	derived	from	nonrandomized	case	series	
without	observation	controls.		Therefore,	the	reported	survival	rates	could	be	a	reflection	of	
patient	selection	bias	as	opposed	to	the	true	curative	effect	of	pulmonary	metastatectomy.		
Randomized	trials	(in	a	multi-institutional	effort)	or	at	least	comparison	with	observation	
controls	need	to	be	performed.	
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